Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
May 27, 2016 09:00 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
May 16, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 16, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use...
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
May 10, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016
April 26, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 26, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
April 25, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 25, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides
April 11, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
April 05, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
March 22, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), reports...
Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark
March 14, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 14, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has obtained...
Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016
March 10, 2016 08:20 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...